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Backgrounds: The long-term efficacy and safety of zotarolimus-eluting stent (ZES) have not been proved in patients with ST-elevation myocardial 
infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI). 
Methods and Results: We evaluated 2,456 patients with STEMI who underwent primary PCI and were enrolled in Korea Acute Myocardial 
Infarction Registry. Median follow up period is 343 days (1-455). Sirolimus-eluting stent (SES) was implanted in 1727 STEMI patients, ZES in 447 
patients and bare metal stent (BMS) in 282 patients. There was no difference in previous history of ischemic heart disease (ZES 7.2 % vs. SES 10.3 
% vs. BMS 12.8 %, P=0.037), but ZES and SES were more often implanted in long lesions (ZES 23.82 ± 5.460 mm vs. SES 26.21 ± 6.282 mm vs. 
BMS 22.00 ± 5.513 mm, P<0.0001) and small arteries (ZES 3.23 ± 0.459 mm vs. SES 3.13 ± 0.344 mm vs. BMS 3.48 ± 0.267 mm, P<0.0001) 
than BMS. The implantation of ZES or SES significantly reduced the incidence of cardiac death (ZES 8.0 % vs. SES 7.3 % vs. BMS 14.0 %, P<0.0001), 
target vessel revascularization (ZES 4.6 % vs. SES 4.5 % vs. BMS 8.0 %, P=0.012) and target lesion revascularization (ZES 3.2 % vs. SES 2.3 % vs. 
BMS 5.1 %, P=0.009; Figure) compared with BMS implantation. However, there were no differences in major adverse cardiac events (MACE) between 
ZES and SES implantation (P=0.321). 
Conclusions: In patients with STEMI who received primary PCI, implantation of ZES significantly reduced long-term MACE and was proved not to be 
inferior to SES. 
